Search Results for: LYN

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
GAB1 GRB2 associated binding protein 1
  • PI3K Cascade
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • PIP3 activates AKT signaling
  • GAB1 signalosome
  • PI3K events in ERBB2 signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Constitutive Signaling by EGFRvIII
  • PI-3K cascade:FGFR1
  • PI-3K cascade:FGFR2
  • PI-3K cascade:FGFR3
  • PI-3K cascade:FGFR4
  • Signaling by FGFR2 in disease
  • Signaling by FGFR4 in disease
  • Signaling by FGFR1 in disease
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • MET activates PI3K/AKT signaling
  • Signaling by FGFR3 fusions in cancer
  • Signaling by FGFR3 point mutants in cancer
  • RET signaling
  • MET activates PTPN11
  • MET activates RAP1 and RAC1
  • MET receptor recycling
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Activated NTRK2 signals through PI3K
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
GAB2 GRB2 associated binding protein 2
  • PI3K Cascade
  • PIP3 activates AKT signaling
  • Signaling by SCF-KIT
  • Signaling by cytosolic FGFR1 fusion mutants
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • RET signaling
  • Interleukin-15 signaling
  • Interleukin receptor SHC signaling
  • FLT3 Signaling
  • FLT3 Signaling
  • STAT5 Activation
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 fusion proteins
  • Signaling by FLT3 fusion proteins
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
GAB3 GRB2 associated binding protein 3
GP6 glycoprotein VI platelet
  • GPVI-mediated activation cascade
  • Cell surface interactions at the vascular wall
  • Platelet Adhesion to exposed collagen
GRIA3 glutamate ionotropic receptor AMPA type subunit 3
  • Activation of AMPA receptors
  • Trafficking of AMPA receptors
  • Trafficking of GluR2-containing AMPA receptors
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Synaptic adhesion-like molecules
  • Glutamic acid
  • Butabarbital
  • Ethanol
  • Lithium cation
  • Aniracetam
  • Talampanel
  • CX-717
  • Fluciclovine (18F)
  • Lithium citrate
  • Lithium succinate
  • Lithium carbonate
  • Syndromic X-linked mental retardation with epilepsy or seizures, including: West syndrome (WS); Partington syndrome (PRTS); Proud syndrome (ACCAG); XMR and epilepsy (XMRE); MRXHF1; XMR OPHN1-related (MRXSO) ; XELBD; XMR, Christianson type (MRXSC); Creatine deficiency syndrome (XL-CDS); Renpenning syndrome (RENS1); Epilepsy and mental retardation limited to females (EFMR); Periventricular nodular heterotopia (PVNH); Hydrocephalus (XLH); XMR, JARID1C related (MRXSJ); Boerjeson-Forssman syndrome (BFLS); CK syndrome (CKS)
HCLS1 hematopoietic cell-specific Lyn substrate 1
HNRNPK heterogeneous nuclear ribonucleoprotein K
  • SUMOylation of RNA binding proteins
  • mRNA Splicing - Major Pathway
  • Processing of Capped Intron-Containing Pre-mRNA
  • HCMV Late Events
  • Artenimol
  • Phenethyl Isothiocyanate
IGHA1 immunoglobulin heavy constant alpha 1
IL1B interleukin 1 beta
  • Interleukin-1 processing
  • CLEC7A/inflammasome pathway
  • Interleukin-10 signaling
  • Interleukin-4 and Interleukin-13 signaling
  • Interleukin-1 signaling
  • Purinergic signaling in leishmaniasis infection
  • Donepezil
  • Minocycline
  • VP025
  • Gallium nitrate
  • Talmapimod
  • Etiprednol dicloacetate
  • VX-702
  • VX-765
  • Andrographolide
  • Canakinumab
  • Rilonacept
  • Foreskin keratinocyte (neonatal)
  • Binimetinib
  • Gevokizumab
  • Dilmapimod
IL2RB interleukin 2 receptor subunit beta
  • RAF/MAP kinase cascade
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • Interleukin-2 signaling
  • Interleukin receptor SHC signaling
  • Denileukin diftitox
  • Aldesleukin
  • Basiliximab
  • Daclizumab
IL7R interleukin 7 receptor
  • Interleukin-7 signaling
  • Interleukin-7 signaling
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • T-B+Severe combined immunodeficiencies (SCIDs), including the following eight diseases: X-linked SCID; Janus kinase-3 (Jak3) deficiency; IL-7 receptor alpha (IL7R alpha) deficiency; IL-2 receptor alpha (IL2R alpha) deficiency; CD45 deficiency; CD3 deficiency; Winged Helix Nude (WHN) deficiency; Immunodeficiency with thynoma
INPP5D inositol polyphosphate-5-phosphatase D
  • Synthesis of PIPs at the plasma membrane
  • Synthesis of IP3 and IP4 in the cytosol
  • Downstream TCR signaling
  • PECAM1 interactions
  • Interleukin receptor SHC signaling
ITPR1 inositol 1,4,5-trisphosphate receptor type 1
  • PLC beta mediated events
  • Effects of PIP2 hydrolysis
  • Elevation of cytosolic Ca2+ levels
  • DAG and IP3 signaling
  • Role of phospholipids in phagocytosis
  • FCERI mediated Ca+2 mobilization
  • Glucagon-like Peptide-1 (GLP1) regulates insulin secretion
  • Ca2+ pathway
  • cGMP effects
  • Regulation of insulin secretion
  • VEGFR2 mediated cell proliferation
  • Ion homeostasis
  • Ion homeostasis
  • CLEC7A (Dectin-1) induces NFAT activation
  • FCGR3A-mediated IL10 synthesis
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Caffeine
  • 1D-myo-inositol 1,4,5-trisphosphate
  • Glycerin
  • Spinocerebellar ataxia (SCA); Machado-Joseph disease (SCA3)
JAK2 Janus kinase 2
  • Interleukin-6 signaling
  • Interleukin-6 signaling
  • MAPK3 (ERK1) activation
  • MAPK1 (ERK2) activation
  • Prolactin receptor signaling
  • Prolactin receptor signaling
  • Signaling by SCF-KIT
  • Signaling by Leptin
  • RMTs methylate histone arginines
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • RAF activation
  • RAF/MAP kinase cascade
  • Interleukin-4 and Interleukin-13 signaling
  • IL-6-type cytokine receptor ligand interactions
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by BRAF and RAF fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Cyclin D associated events in G1
  • Interferon gamma signaling
  • Regulation of IFNG signaling
  • Regulation of IFNG signaling
  • Interleukin-20 family signaling
  • Interleukin-35 Signalling
  • Signaling by Erythropoietin
  • Interleukin-12 signaling
  • Interleukin-12 signaling
  • Interleukin-23 signaling
  • Interleukin-23 signaling
  • Interleukin-27 signaling
  • Interleukin-27 signaling
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Erythropoietin activates Phospholipase C gamma (PLCG)
  • Erythropoietin activates STAT5
  • Erythropoietin activates RAS
  • Erythropoietin activates RAS
  • Interleukin receptor SHC signaling
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Potential therapeutics for SARS
  • Growth hormone receptor signaling
  • Growth hormone receptor signaling
  • Factors involved in megakaryocyte development and platelet production
  • 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one
  • XL019
  • 5-phenyl-1H-indazol-3-amine
  • 4-(3-amino-1H-indazol-5-yl)-N-tert-butylbenzenesulfonamide
  • 4-[(2-{4-[(CYCLOPROPYLCARBAMOYL)AMINO]-1H-PYRAZOL-3-YL}-1H-BENZIMIDAZOL-6-YL)METHYL]MORPHOLIN-4-IUM
  • Ruxolitinib
  • Tofacitinib
  • Baricitinib
  • Entrectinib
  • Fostamatinib
  • Fedratinib
  • Zanubrutinib
  • Pralsetinib
  • Polycythemia vera
KHDRBS1 KH RNA binding domain containing, signal transduction associated 1
  • PTK6 Regulates Proteins Involved in RNA Processing
KIT KIT proto-oncogene, receptor tyrosine kinase
  • PIP3 activates AKT signaling
  • Signaling by SCF-KIT
  • Signaling by SCF-KIT
  • Regulation of KIT signaling
  • Regulation of KIT signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
  • Dasatinib-resistant KIT mutants
  • Imatinib-resistant KIT mutants
  • KIT mutants bind TKIs
  • Masitinib-resistant KIT mutants
  • Nilotinib-resistant KIT mutants
  • Regorafenib-resistant KIT mutants
  • Signaling by kinase domain mutants of KIT
  • Sunitinib-resistant KIT mutants
  • Signaling by juxtamembrane domain KIT mutants
  • Sorafenib-resistant KIT mutants
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by extracellular domain mutants of KIT
  • Sorafenib
  • Imatinib
  • Dasatinib
  • Sunitinib
  • Phosphonotyrosine
  • Nilotinib
  • XL820
  • OSI-930
  • ABT-869
  • Pazopanib
  • Midostaurin
  • Regorafenib
  • Ponatinib
  • Lenvatinib
  • Ancestim
  • Fostamatinib
  • Erdafitinib
  • Amuvatinib
  • Pexidartinib
  • Ripretinib
  • Avapritinib
  • Piebaldism
  • Acute myeloid leukemia (AML)
LCP2 lymphocyte cytosolic protein 2
  • GPVI-mediated activation cascade
  • Generation of second messenger molecules
  • Generation of second messenger molecules
  • DAP12 signaling
  • FCERI mediated MAPK activation
  • FCERI mediated Ca+2 mobilization
  • FCERI mediated Ca+2 mobilization
LIME1 Lck interacting transmembrane adaptor 1
MAP4K1 mitogen-activated protein kinase kinase kinase kinase 1
  • Fostamatinib
MAPK3 mitogen-activated protein kinase 3
  • MAPK3 (ERK1) activation
  • RAF-independent MAPK1/3 activation
  • ISG15 antiviral mechanism
  • Spry regulation of FGF signaling
  • Frs2-mediated activation
  • ERK/MAPK targets
  • ERK/MAPK targets
  • ERKs are inactivated
  • Regulation of actin dynamics for phagocytic cup formation
  • Oxidative Stress Induced Senescence
  • Senescence-Associated Secretory Phenotype (SASP)
  • Oncogene Induced Senescence
  • Oncogene Induced Senescence
  • FCERI mediated MAPK activation
  • Regulation of HSF1-mediated heat shock response
  • NCAM signaling for neurite out-growth
  • RSK activation
  • Signal transduction by L1
  • Activation of the AP-1 family of transcription factors
  • Thrombin signalling through proteinase activated receptors (PARs)
  • Negative regulation of FGFR1 signaling
  • Negative regulation of FGFR2 signaling
  • Negative regulation of FGFR3 signaling
  • Negative regulation of FGFR4 signaling
  • RHO GTPases Activate WASPs and WAVEs
  • RHO GTPases Activate NADPH Oxidases
  • RAF/MAP kinase cascade
  • MAP2K and MAPK activation
  • Negative feedback regulation of MAPK pathway
  • Negative regulation of MAPK pathway
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • RNA Polymerase I Promoter Opening
  • Signal attenuation
  • Advanced glycosylation endproduct receptor signaling
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • ESR-mediated signaling
  • RUNX2 regulates osteoblast differentiation
  • Regulation of PTEN gene transcription
  • Regulation of the apoptosome activity
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • Suppression of apoptosis
  • Signaling downstream of RAS mutants
  • Signaling by MAP2K mutants
  • Signaling by RAF1 mutants
  • FCGR3A-mediated phagocytosis
  • Growth hormone receptor signaling
  • Sulindac
  • Acetylsalicylic acid
  • Minocycline
  • Arsenic trioxide
  • Purvalanol
  • 5-iodotubercidin
  • Seliciclib
  • Cholecystokinin
  • Ulixertinib

Page 4 out of 7 pages